Clinical trials: Influenza Vaccine
Influenza, SARS (Severe Acute Respiratory Syndrome)
Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)
Respiratory infections such as colds, flu and pneumonia affect millions of people around the world every year. Most cases are mild, but some people become very unwell.
- Conditions
- Influenza, SARS (Severe Acute Respiratory Syndrome), Respiratory Viral Infection, Respiratory Tract Infections
- Trial name
- PREDICT-ILI (NCT04664075)
- Testing
- Respiratory infections
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Imperial College London
Influenza, Vaccination
Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine
This multi-site study assesses the impact of text message reminders on the receipt of the second dose of influenza vaccine, and takes place primarily in practices from the American Academy of Pediatrics (AAP) Pediatric Research…
- Trial name
- F2T (NCT03287830)
- Testing
- Text message influenza vaccine reminders
- Where
- 3 sites in United States
- Volunteers
- 2,105 people
- Sponsor
- Columbia University
Influenza
A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults
Recombinant hemagglutinin has been shown to induce protective neutralising antibodies against avian influenza virus but is relatively non-immunogenic.
- Trial name
- FLU003 (NCT02335164)
- Testing
- recombinant influenza hemagglutinin, Advax1, Advax2
- Where
- Australia
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Influenza - Type A Strains
Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.
The purposes of this study are to determine if MEDI8852 administered with standard of care (oseltamivir) will reduce the time to normalization of respiratory function for adults who are hospitalized with influenza caused by Type…
- Trial name
- NCT03028909
- Testing
- Oseltamivir, MEDI8852
- Sponsor
- MedImmune LLC
Influenza
Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1
In agreement with the World Organization of the Health (WHO), during the annual epidemics of influenza they become infected between 10-20 % of the total population, appearing from a feverish disease up to leading to the…
- Trial name
- NCT00989274
- Testing
- Vaccine Sanofi A(H1N1) 15 ug & trivalent, Vaccine Sanofi (H1N1) 15 ug.nonadyuvante, Vaccine Sanofi A(H1N1) 7.5 ug
- Where
- Mexico
- Sponsor
- Instituto Nacional de Salud Publica, Mexico
Influenza, Behavior and Behavior Mechanisms
Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake
In randomized clinical trials and observational studies, influenza vaccination has been shown to be effective in reducing influenza-related illness, hospitalizations, cardiovascular events, and mortality in select populations.
- Trial name
- NUDGE-FLU (NCT05542004)
- Testing
- Behavioral Economic Principles
- Where
- Denmark
- Volunteers
- 964,870 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
Influenza Human
Clinical Validation of the Point-of-Care MSD Influenza Test
The primary objective of this study is to evaluate the performance of the MSD® Influenza Test in detecting influenza A and influenza B in subjects presenting with influenza-like-illness (ILI).
- Trial name
- NCT00863343
- Testing
- Public Health Notification
- Where
- 3 sites in United States
- Volunteers
- 391 people
- Sponsor
- Meso Scale Diagnostics, LLC.
Influenza Vaccine in Scleroderma
Influenza Vaccination in Patients With Scleroderma
The safety and efficacy of vaccination against influenza in patients with scleroderma is not clear. The objective of this study is to assess its safety and efficacy in 50 patients with scleroderma in comparison with 30 controls
- Trial name
- NCT01002508
- Testing
- Influenza vaccine
- Where
- Israel
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma
B-Cell Hematologic Malignancy Vaccination Registry
The goal of this study is to develop a vaccination registry system for Aurora Health Care patients newly diagnosed with MM and other B-Cell Hematologic Malignancies in order to prospectively characterize vaccination history and…
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Waldenstrom Macroglobulinemia, Lymphocytosis
- Trial name
- HMvax-Regist (NCT02298816)
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Influenza Type A, Influenza Type B
Influenza A+B Test Kit Performance Study
Prospective clinical study on the performance of an Influenza A+B rapid test kit. The main goal is to establish the sensitivity and specificity (i.e. how accurate the test is) when compared to a gold standard.
- Trial name
- NCT03895268
- Testing
- ALiA Analyser, Influenza A+B Test Kit
- Where
- Hong Kong
- Volunteers
- 600 people
- Sponsor
- Sanwa BioTech Limited
Influenza, Influenza, Human
Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks
Influenza outbreaks are a prevalent event in nursing homes (NHs). We will study baloxavir compared to oseltamivir when used for influenza prophylaxis when facilities identify an index incident case of influenza.
- Conditions
- Influenza, Influenza, Human, Influenza -Like Illness
- Trial name
- NCT05012189
- Testing
- Oseltamivir, Baloxavir
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Insight Therapeutics, LLC
Influenza Virus Infection, Trained Immunity
Effects of BCG on Influenza Induced Immune Response
In the present study, the investigators want to investigate whether prior BCG-vaccination improves the efficacy of influenza ("the flu") vaccination in young and/or old healthy volunteers and consequently could protect against…
- Trial name
- NCT02114255
- Testing
- BCG
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV)
Respiratory Virus Hospitalization Study (FLU 003 Plus)
Following the sudden and unexpected emergence of influenza A(H1N1)pdm09 (2009 H1N1) virus, this observational study was initiated to estimate rates of morbidity and mortality and to examine predictors of severity among…
- Conditions
- Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
- Trial name
- NCT01056185
- Where
- 63 sites in United States, Argentina and 10 more
- Volunteers
- 1,000 people
- Sponsor
- University of Minnesota
Influenza Immunization
Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older
The purpose of this study is to evaluate a pandemic flu H5 strain messenger ribonucleic acid (mRNA) vaccine at 3 dose levels (low, medium, and high) in comparison with placebo in 276 healthy adult participants to select the…
- Trial name
- NCT06727058
- Testing
- Pandemic flu H5 mRNA vaccine
- Where
- 14 sites in United States
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)
The objectives of this Phase I/II study are to assess the safety and immunogenicity of two different dose levels of a non-adjuvanted H5N1 influenza vaccine in a healthy young adult population.
- Trial name
- NCT00517517
- Testing
- Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation
- Where
- 4 sites in Hong Kong, Singapore
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza Vaccination, Influenza
Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls
LAIV shedding studies in children could be an important way to confirm whether impediments to viral replication do indeed explain these observed reductions in vaccine effectiveness(VE), whether prior vaccination has any influence…
- Conditions
- Influenza Vaccination, Influenza, Vaccination
- Trial name
- Flushed (NCT03104790)
- Testing
- Fluenz Tetra (The two groups are defined by immunisation history, all receive the same intervention in the study)
- Where
- 3 sites in United Kingdom
- Volunteers
- 373 people, healthy volunteers welcome
- Sponsor
- Public Health England
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012
This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT03022435
- Testing
- TIV, High-Dose TIV, LAIV
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Stanford University
Flu
FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care
Adjuvanted flu vaccine, Fluad, is not immunologically inferior to HD influenza vaccine in older persons living in long-term care.
- Trial name
- NCT03694808
- Testing
- Fluad Vaccine, Fluzone HD Vaccine
- Where
- 2 sites in United States
- Volunteers
- 478 people
- Sponsor
- David H. Canaday
ARDS, Covid19
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome…
- Conditions
- ARDS, Covid19, Influenza, Human
- Trial name
- AVM0703 (NCT04366115)
- Testing
- AVM0703
- Volunteers
- 16 people
- Sponsor
- AVM Biotechnology Inc
Non Small Cell Lung Cancer, Influenza Vaccine
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
This project is to assess the immunogenicity, safety and overall survival impact of intramuscular injection of trivalent influenza vaccine in non-small cell lung cancer (NSCLC) patients with PD-1/PD-L1 inhibitor treatment.
- Trial name
- NCT04355806
- Testing
- PD-1/PD-L1 inhibitors, Inactivated trivalent influenza vaccine
- Where
- 2 sites in China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.